[Drug interaction during therapy with tolbutamide. The influence of some commonly used drugs on plasma level and half life in diabetic out-patients (author's transl)].
Tolbutamide belongs to those drugs responsible for the majority of drug interactions. E.g. Tolbutamide metabolism has been shown to be inhibited by coumarole derivatives. We determined plasma-tolbutamide levels in diabetic out-patients for one year. The results obtained indicate no difference in patients additionally treated with either digoxin or digoxin and alpha-methyldopa, or buformin and phenprocumone as compared with control groups. Interactions with respect to biotransformation should not be expected as far as digoxin, alpha-Methyldopa, or buformine were concerned, since these compounds do not share a common metabolic pathway with tolbutamide. In a different group of patients the elimination half life of tolbutamide under the influence of phenprocoumone was additonally determined. Differences could not be detected. This finding can be explained by means of enzyme-kinetic considerations, since phenprocumone, in contrast to dicoumarole, becomes metabolized according to a first order reaction. Competitive enzyme inhibition with tolbutamide which is metabolized similarly to phenprocoumone, therefore appears improbable.
D002026:Buformin / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004077:Digoxin / Q000378:metabolism; D004347:Drug Interactions; D004791:Enzyme Inhibitors; D006207:Half-Life; D006801:Humans; D008750:Methyldopa / Q000378:metabolism; D010644:Phenprocoumon / Q000378:metabolism; D014044:Tolbutamide / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D008750:Methyldopa; D004077:Digoxin; D014044:Tolbutamide; D010644:Phenprocoumon; D002026:Buformin
Arzneimittelwechselwirkungen bei der Therapie mit Tolbutamid Beeinflussung von Serumspiegel und Halbwertzeit durch einige gebräuchliche Pharmaka bei Altersdiabetikern.